Minoryx announces enrollment of first patients with cerebral Adrenoleukodystrophy (cALD) in US Phase 3 clinical trial, CALYX

by Ysios Capital

11 months ago
leriglitazona, cerebral Adrenoleukodystrophy (cALD), CALIX, X-linked Adrenoleukodystrophy (X-ALD), Minoryx Therapeutics

As part of CALYX, Minoryx is conducting an extensive pre-screening MRI-based campaign aimed at identifying eligible adult X-ALD patients with cerebral Adrenoleukodystrophy (cALD)

Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe

by Ysios Capital

2 years ago
Minoryx Therapeutics, Leriglitazona, X-ALD

Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders and the Neuraxpharm Group (“Neuraxpharm”), a leading E...

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

by Minoryx Therapeutics

4 years ago
financing, neurodegenerative diseases, Minoryx Therapeutics, leriglitazone, biomedicine, EIB

Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders, today announces that th...

Minoryx Therapeutics, participated by Ysios and Caixa Capital Risc, and Sperogenix Therapeutics enter into an exclusive license agreement

by Ysios Capital

4 years ago
adrenoleucodistrofia, leriglitazona, Minoryx Therapeutics, Ysios Capital, Caixa Capital Risc, Sperogenix Therapeutics

Sperogenix Therapeutics, a platform company dedicated to developing and commercializing rare disease therapeutics in China, and Minoryx Therapeutics, a company that specializes in the development of i...

La inversión en las startups de las ciencias de la vida y la salud en Cataluña supera por cuarto año consecutivo los 100 millones de euros

by Biocat

4 years ago
inversión, startups, Biopharma, salud digital, Asabys Partners, Alta Life Sciences, Invivo Capital, Ysios Capital, Minoryx Therapeutics, Inbrain Neuroelectronics, Mediktor

El “Estudio de inversión en el sector de las ciencias de la vida y la salud en Cataluña 2020” revela la buena salud del ecosistema, que casi ha igualado durante el primer semestre de 2020 el cap...

Minoryx Therapeutics appoints Didier Le Normand as Group Chief Financial Officer (CFO) and General Manager of its Belgian subsidiary

by Minoryx Therapeutics

6 years ago
Minoryx Therapeutics, appointment, rare diseases

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has appointed Didier Le Normand as Group CFO as well as General Manager of its...

Minoryx Therapeutics extends its activities in Belgium

by Minoryx Therapeutics

6 years ago
Minoryx Therapeutics, subsidiary, biotechnology

Minoryx Therapeutics extends its activities in Belgium

Minoryx Therapeutics raises €21.3M in Series B funding round

by Ysios Capital

6 years ago
Minoryx Therapeutics, MIN-102, adrenomieloneuropatía

The funding round was led by Fund+, joined by SFPI-FPIM, S.R.I.W. and Sambrinvest, in addition to all Series A investors (Ysios Capital, Kurma Partners, Roche Venture Fund, Idinvest Partners, Chiesi V...

Minoryx successfully completes phase 1 clinical trial for lead candidate MIN-102

by Professional Newco

8 years ago
Minoryx Therapeutics, MIN-102, X-linked adrenoleukodystrophy

Minoryx Therapeutics – a drug development company specialized in the discovery and development of new drugs for orphan diseases, which has R& D laboratories at the Barcelona Science Park– announce...

Minoryx Therapeutics receives European Orphan Drug Designation for its lead candidate MIN-102

by Professional Newco

8 years ago
Minoryx Therapeutics, MIN-102, Orphan Drug Designation, European Medicines Agency (EMA), X-linked adrenoleukodystrophy (X-ALD)

MIN-102 is a selective PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept in multiple animal models. Phase I studi...

Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102

by Ysios Capital

8 years ago
X-ALD, Minoryx Therapeutics, MIN-102, Ysios Capital

MIN-102 is a differentiated PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept. The aim of the Phase 1 study is to...

Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)

by Ysios Capital

9 years ago
orphan diseases, Minoryx Therapeutics, Caixa Capital Risc, Ysios Capital, Ysios BioFund II Innvierte, SEE-Tx, X-ALD, MIN-102, Roche Venture Fund, Kurma Partners, Idinvest Partners, Chiesi Ventures, HealthEquity

Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substantial syndicate of new investors including Kurma Partners, Roche Venture Fund, Idinvest Partners ...